NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
Incyte Corporation
Amgen
Janssen Research & Development, LLC
Chongqing Peg-Bio Biopharm Co., Ltd.
Amgen
Servier